Publicaciones (27) Publicaciones de JUAN ANDRES PARGA MARTIN

2024

  1. Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson’s disease models

    Stem Cell Research and Therapy, Vol. 15, Núm. 1

2023

  1. Combined cell-based therapy strategies for the treatment of Parkinson's disease: Focus on mesenchymal stromal cells

    Neural Regeneration Research, Vol. 18, Núm. 3, pp. 478-484

2022

  1. Nigral Neurons Degenerating in Parkinson's Disease Express the Angiotensin Receptor Type 1 Gene

    Movement Disorders

2021

  1. Dopamine regulates adult neurogenesis in the ventricular-subventricular zone via dopamine D3 angiotensin type 2 receptor interactions

    Stem Cells, Vol. 39, Núm. 12, pp. 1778-1794

  2. Dose-dependent effect of mesenchymal stromal cells co-grafted with dopaminergic neurons in a Parkinson's disease rat model

    Journal of Cellular and Molecular Medicine, Vol. 25, Núm. 20, pp. 9884-9889

  3. Nrf2 activation and downstream effects: Focus on parkinson’s disease and brain angiotensin

    Antioxidants, Vol. 10, Núm. 11

2019

  1. Interaction between Angiotensin Type 1, Type 2, and Mas Receptors to Regulate Adult Neurogenesis in the Brain Ventricular-Subventricular Zone

    Cells, Vol. 8, Núm. 12

2018

  1. Angiotensin II induces oxidative stress and upregulates neuroprotective signaling from the NRF2 and KLF9 pathway in dopaminergic cells

    Free Radical Biology and Medicine, Vol. 129, pp. 394-406

  2. Data on the effect of Angiotensin II and 6-hydroxydopamine on reactive oxygen species production, antioxidant gene expression and viability of different neuronal cell lines

    Data in Brief

  3. Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans

    Molecular Neurobiology, Vol. 55, Núm. 7, pp. 5847-5867

  4. Prostaglandin EP2 Receptors Mediate Mesenchymal Stromal Cell-Neuroprotective Effects on Dopaminergic Neurons

    Molecular Neurobiology, Vol. 55, Núm. 6, pp. 4763-4776

2016

  1. Effects of rho kinase inhibitors on grafts of dopaminergic cell precursors in a rat model of Parkinson’s disease

    Stem Cells Translational Medicine, Vol. 5, Núm. 6, pp. 804-815

2013

  1. Derivation and Expansion Using Only Small Molecules of Human Neural Progenitors for Neurodegenerative Disease Modeling

    PLoS ONE, Vol. 8, Núm. 3

  2. Discovery of neuritogenic compound classes inspired by natural products

    Angewandte Chemie - International Edition, Vol. 52, Núm. 36, pp. 9576-9581

  3. Highly enantioselective catalytic synthesis of neurite growth-promoting secoyohimbanes

    Chemistry and Biology, Vol. 20, Núm. 4, pp. 500-509

2012

  1. Discovery of inhibitors of microglial neurotoxicity acting through multiple mechanisms using a stem-cell-based phenotypic assay

    Cell Stem Cell, Vol. 11, Núm. 5, pp. 620-632

  2. Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease

    Age, Vol. 34, Núm. 4, pp. 863-880

2010

  1. Effect of inhibitors of NADPH oxidase complex and mitochondrial ATP-sensitive potassium channels on generation of dopaminergic neurons from neurospheres of mesencephalic precursors

    Developmental Dynamics, Vol. 239, Núm. 12, pp. 3247-3259

2009

  1. The mitochondrial ATP-sensitive potassium channel blocker 5-hydroxydecanoate inhibits toxicity of 6-hydroxydopamine on dopaminergic neurons

    Neurotoxicity Research, Vol. 15, Núm. 1, pp. 82-95

2008

  1. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS

    Neurobiology of Disease, Vol. 31, Núm. 1, pp. 58-73